The notes are additional notes and form part of the same series as Valeant's existing 5.500% senior secured notes due 2025.
Valeant used the net proceeds from the offering of the notes, along with cash on hand, to prepay (on a pro rata basis) a portion of its outstanding Series F Tranche B Term Loans due 2022 and to pay related fees and expenses.
Subsequent to the closing of the offering and the related prepayment, the company successfully completed the repricing of its Series F Tranche B Term Loans.
The amendment reduces the annual interest rate on the Series F Tranche B Term Loans by 1.25% and makes certain other changes.
Valeant Pharmaceuticals International develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US